Status:
TERMINATED
Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors
Lead Sponsor:
The Netherlands Cancer Institute
Conditions:
Brain Tumor
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to evaluate anatomical and functional changes during RT for patients receiving fractionated RT for brain tumors. Anatomical changes during RT will be registered and analyzed and if nee...
Eligibility Criteria
Inclusion
- Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy.
- Brain metastasis (from a solid extracranial tumor) eligible for treatment with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy.
- Also, postoperative patients with a macroscopic residual tumor lesion can be included (the diagnosis of residual diseases is defined by the treating neurosurgeon or on the MRI executed within 24 hours after the surgery, the diagnosis of residual macroscopic disease should always be confirmed during the neuro-oncology multidisciplinary meeting).
Exclusion
- Patients receiving Whole Brain RT (WBRT)
- Patient with a poor kidney function (GFR \< 30 mL/min; CKD 4 and 5; patients on dialysis and patients with acute kidney insufficiency)
- None, doubtful or very small (\<5 mm in its largest dimension) contrast enhancing lesion
- Patients with a contraindication for MRI
Key Trial Info
Start Date :
January 12 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 10 2020
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03394716
Start Date
January 12 2018
End Date
December 10 2020
Last Update
April 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Antoni van Leeuwenhoek
Amsterdam, North Holland, Netherlands, 1066CX